ReviewBioMed research international2015
Functional roles of calreticulin in cancer biology.
Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05874193 (A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma), which is not on this map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.
- Calreticulin Expression in Human Carcinomas: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2023Pooled it
- Review
- Goniothalamin as a Styryl-Lactone Toxicophore in Cancer Models: Electrophile-Driven DNA Damage, Reactive Oxygen Species-Endoplasmic Reticulum Stress Signaling and Detoxification-Relevant Safety Considerations.Journal of biochemical and molecular toxicology · 2026Review
- Myeloid Malignancies Beyond the Cell: Targeting the Tumour Microenvironment with Next-Generation Immunotherapies.Cancers · 2026Review
- C-MYC as a key effector of WNT, PI3K/AKT, MAPK, and TGF-β signaling pathways in regulation of epithelial-mesenchymal transition during tumor metastasis.Cancer cell international · 2026Review
- CALR Type 1-Like Mutations Increase Endoplasmic Reticulum Free CaCell biology international · 2025Article
- Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression.Molecular oncology · 2025Article
- Article
- pUS6 in pseudorabies virus participates in the process of inhibiting antigen presentation by inhibiting the assembly of peptide loading complex.BMC veterinary research · 2024Article
- The Role of Mutated Calreticulin in the Pathogenesis ofInternational journal of molecular sciences · 2024Article
- RecombinantPathogens (Basel, Switzerland) · 2024Article
- Liver X Receptors (LXRs) in cancer-an Eagle's view on molecular insights and therapeutic opportunities.Frontiers in cell and developmental biology · 2024Review
- Calreticulin as a marker and therapeutic target for cancer.Clinical and experimental medicine · 2023Review
- Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy.International journal of pharmaceutics · 2023Review
- Proteome derangement in malignant epithelial cells and its stroma following exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.Archives of toxicology · 2023Article
- Optimizing simple calreticulin upregulation strategies inBiology methods & protocols · 2023Article
- Calreticulin Expression Controls Cellular Redox, Stemness, and Radiosensitivity to Function as a Novel Adjuvant for Radiotherapy in Neuroblastoma.Oxidative medicine and cellular longevity · 2023Article
- Endometriosis Stem Cells as a Possible Main Target for Carcinogenesis of Endometriosis-Associated Ovarian Cancer (EAOC).Cancers · 2022Review
- Radiosensitization of calreticulin-overexpressing human glioma cell line by the polyphenolic acetate 7, 8-diacetoxy-4-methylcoumarin.Cancer reports (Hoboken, N.J.) · 2022Article
- Combined In Vitro Toxicity and Immunogenicity of Cold Plasma and Pulsed Electric Fields.Biomedicines · 2022Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calreticulin is a highly conserved endoplasmic reticulum chaperone protein which participates in various cellular processes. It was first identified as a Ca(2+)-binding protein in 1974. Accumulated evidences indicate that calreticulin has great impacts for the development of different cancers and the effect of calreticulin on tumor formation and progression may depend on cell types and clinical stages. Cell surface calreticulin is considered as an "eat-me" signal and promotes phagocytic uptake of cancer cells by immune system. Moreover, several reports reveal that manipulation of calreticulin levels profoundly affects cancer cell proliferation and angiogenesis as well as differentiation. In addition to immunogenicity and tumorigenesis, interactions between calreticulin and integrins have been described during cell adhesion, which is an essential process for cancer metastasis. Integrins are heterodimeric transmembrane receptors which connect extracellular matrix and intracellular cytoskeleton and trigger inside-out or outside-in signaling transduction. More and more evidences reveal that proteins binding to integrins might affect integrin-cytoskeleton interaction and therefore influence ability of cell adhesion. Here, we reviewed the biological roles of calreticulin and summarized the potential mechanisms of calreticulin in regulating mRNA stability and therefore contributed to cancer metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.